Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Vos

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Diabetologia|February 6, 2010
Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary careM Y Bertram, S S Lim, J J Barendregt, et al.
Journal of Cardiovascular Risk|March 10, 2001
A model for predicting the future incidence of coronary heart disease within percentiles of coronary heart disease riskJ J McNeil, A Peeters, D Liew, et al.
Psychological Medicine|July 12, 2012
Global prevalence of anxiety disorders: a systematic review and meta-regressionA J Baxter, K M Scott, T Vos, et al.
Biotechnology and Bioengineering|January 20, 1993
Continuous bioconversion of n-octane to octanoic acid by recombinant Escherichia coli (alk(+)) growing in a two-liquid-phase ChemostatO Favre-Bulle, E Weenink, T Vos, et al.
British Journal of Experimental Pathology|October 1, 1982
The glomerular polyanion (GPA) of the rat kidney II. GPA loss in vitro by a vasoactive serum fractionW W Bakker, J T Vos, J Scholma, et al.
The Medical Journal of Australia|July 29, 2000
The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factorsC D Mathers, E T Vos, C E Stevenson, et al.
Bulletin of the World Health Organization|December 4, 2001
The burden of disease and injury in AustraliaC D Mathers, E T Vos, C E Stevenson, et al.
Immunobiology|October 1, 1989
Thymocytes reacting with heterologous antibodies against GP 330 in autologous immune complex glomerulopathy (AICG) in the rat. The relation between susceptibility for AICG and anti-GP 330-binding thymocytesW M Bagchus, P J Hoedemaeker, J T Vos, et al.
Clinical and Experimental Immunology|March 1, 1986
The specificity of nephritogenic antibodies. III. Binding of anti-Fx1A antibodies in glomeruli is dependent on dual specificityW M Bagchus, J T Vos, P J Hoedemaeker, et al.
The Medical Journal of Australia|January 5, 2002
Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteriaS S Lim, T Vos, A Peeters, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Diabetologia|February 6, 2010
Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary careM Y Bertram, S S Lim, J J Barendregt, et al.
Journal of Cardiovascular Risk|March 10, 2001
A model for predicting the future incidence of coronary heart disease within percentiles of coronary heart disease riskJ J McNeil, A Peeters, D Liew, et al.
Psychological Medicine|July 12, 2012
Global prevalence of anxiety disorders: a systematic review and meta-regressionA J Baxter, K M Scott, T Vos, et al.
Biotechnology and Bioengineering|January 20, 1993
Continuous bioconversion of n-octane to octanoic acid by recombinant Escherichia coli (alk(+)) growing in a two-liquid-phase ChemostatO Favre-Bulle, E Weenink, T Vos, et al.
British Journal of Experimental Pathology|October 1, 1982
The glomerular polyanion (GPA) of the rat kidney II. GPA loss in vitro by a vasoactive serum fractionW W Bakker, J T Vos, J Scholma, et al.
The Medical Journal of Australia|July 29, 2000
The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factorsC D Mathers, E T Vos, C E Stevenson, et al.
Bulletin of the World Health Organization|December 4, 2001
The burden of disease and injury in AustraliaC D Mathers, E T Vos, C E Stevenson, et al.
Immunobiology|October 1, 1989
Thymocytes reacting with heterologous antibodies against GP 330 in autologous immune complex glomerulopathy (AICG) in the rat. The relation between susceptibility for AICG and anti-GP 330-binding thymocytesW M Bagchus, P J Hoedemaeker, J T Vos, et al.
Clinical and Experimental Immunology|March 1, 1986
The specificity of nephritogenic antibodies. III. Binding of anti-Fx1A antibodies in glomeruli is dependent on dual specificityW M Bagchus, J T Vos, P J Hoedemaeker, et al.
The Medical Journal of Australia|January 5, 2002
Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteriaS S Lim, T Vos, A Peeters, et al.
Pageof 6